Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus
NCT00321438 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2009-05-18
Summary
The purpose of this study is to measure viral tropism over time in subjects with X4-tropic or non-phenotypeable virus while receiving standard of care therapy. This is an observational study. No investigational treatment will be administered through this study.
Conditions
- HIV Infection
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials, MD · GlaxoSmithKline
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-07-31
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05917509 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants
NCT02269917 ·Status: COMPLETED ·Phase: PHASE3
-
Immunological and Viral Response to Antiretrovirals in HIV Patients With CD4 Cell Count Below 100
NCT00385957 ·Status: COMPLETED ·Phase: PHASE4
-
Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults
NCT00820118 ·Status: COMPLETED ·Phase: PHASE2
-
Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia
NCT01378910 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care
NCT03227861 ·Status: COMPLETED ·Phase: PHASE3
-
Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140
NCT00123890 ·Status: TERMINATED ·Phase: PHASE3
-
Cohort of Patients Naive of Antiretroviral Treatment at Enrollment
NCT03137797 ·Status: COMPLETED
-
"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"
NCT05761509 ·Status: COMPLETED
-
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
NCT05349838 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects
NCT01029548 ·Status: COMPLETED
-
GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
NCT00257621 ·Status: COMPLETED ·Phase: PHASE2
-
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
NCT00738569 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of Antiretroviral Therapy During Acute HIV Infection
NCT00705926 ·Status: COMPLETED ·Phase: PHASE1
-
A Long-term Follow-up of the HIV-NAT Cohort
NCT00411983 ·Status: RECRUITING
-
Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens
NCT02191319 ·Status: COMPLETED
-
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
NCT00242840 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects
NCT01024556 ·Status: COMPLETED
-
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
NCT01968551 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
NCT01297127 ·Status: COMPLETED
-
Analytical Treatment Interruption in HIV Positive Patients
NCT02590354 ·Status: COMPLETED ·Phase: NA
-
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
NCT02121795 ·Status: COMPLETED ·Phase: PHASE3
-
Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens
NCT00627055 ·Status: COMPLETED ·Phase: PHASE4
-
Strategic Timing of Antiretroviral Treatment
NCT00867048 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
NCT01252940 ·Status: COMPLETED ·Phase: PHASE3